87
Views
6
CrossRef citations to date
0
Altmetric
Original Article

Drug-free macromolecular therapeutics exhibit amplified apoptosis in G2/M phase arrested cells

, , &
Pages 566-572 | Received 23 May 2018, Accepted 03 Sep 2018, Published online: 10 Dec 2018

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics 2016. CA: Cancer J Clin. 2016;66:7–30.
  • Seyfizadeh N, Seyfizadeh N, Hasenkamp J, et al. A molecular perspective on rituximab: a monoclonal antibody for B cell non-Hodgkin lymphoma and other affections. Crit Rev Oncol Hemat. 2016;97:275–290.
  • Taylor RP, Lindorfer MA. Antigenic modulation and rituximab resistance. Semin Hematol. 2010;47:124–132.
  • Chu TW, Yang J, Zhang R, et al. Cell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces apoptosis. ACS Nano. 2014;8:719–730.
  • Li L, Yang J, Wang J, et al. Drug-free macromolecular therapeutics induce apoptosis via calcium influx and mitochondrial signaling pathway. Macromol Biosci. 2018;18:1700196.
  • Li L, Yang J, Wang J, et al. Amplification of CD20 cross-linking in rituximab-resistant B-lymphoma cells enhances apoptosis induction by drug-free macromolecular therapeutics. ACS Nano 2018;12:3658–3670.
  • Wu K, Liu J, Johnson RN, et al. Drug-free macromolecular therapeutics: induction of apoptosis by coiled-coil mediated crosslinking of antigens on cell surface. Angew Chem Int Ed. 2010;49:1451–1455.
  • Zhang L, Fang Y, Yang J, et al. Drug-free macromolecular therapeutics: impact of structure on induction of apoptosis in Raji B cells. J Control Release. 2017;263:139–150.
  • Hartley JM, Zhang R, Gudheti M, et al. Tracking and quantifying polymer therapeutic distribution on a cellular level using 3D dSTORM. J Control Release. 2016;231:50–59.
  • Raucher D, Sheetz MP. Membrane expansion increases endocytosis rate during mitosis. J Cell Biol. 1999;144:497–506.
  • Boucrot E, Kirchhausen T. Endosomal recycling controls plasma membrane area during mitosis. Proc Natl Acad Sci USA. 2007;104:7939–7944.
  • Kim JA, Aberg C, Salvati A, et al. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat Nanotechnol. 2011;7:62–68.
  • Gao H, Hu G, Zhang Q, et al. Pretreatment with chemotherapeutics for enhanced nanoparticles accumulation in tumor: the potential role of G2 cycle retention effect. Sci Rep. 2014;4:4492.
  • Manchado E, Guillamot M, Malumbres M. Killing cells by targeting mitosis. Cell Death Differ. 2012;19:369–377.
  • Chan KS, Koh CG, Li HY. Mitosis-targeted anti-cancer therapies: where they stand. Cell Death Dis. 2012;3:e411.
  • Li L, Sun W, Zhang Z, et al. Time-staggered delivery of docetaxel and H1-S6A,F8A peptide for sequential dual-strike chemotherapy through tumor priming and nuclear targeting. J Control Release. 2016;232:62–74.
  • Zhou Y, Yang J, Rhim JS, et al. HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects. J Control Release. 2013;172:946–953.
  • Zhou Y, Yang J, Zhang R, et al. Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel. Eur J Pharm Biopharm. 2015;89:107–115.
  • Yang J, Li L, Kopeček J. Biorecognition: A key to drug-free macromolecular therapeutics. Biomaterials. 2019;190–191;11–23.
  • Zhang N, Khawli LA, Hu P, et al. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Clin Cancer Res. 2005;11:5971–5980.
  • Moody PR, Sayers EJ, Magnusson JP, et al. Receptor crosslinking: a general method to trigger internalization and lysosomal targeting of therapeutic Receptor:Ligand Complexes. Mol Ther. 2015;23:1888–1898.
  • Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G2/M. Mol Cell Biol. 1999;19:8469–8478.
  • Haldar S, Basu A, Croce CM. Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Res. 1998;58:1609–1615.
  • Sun W, Li L, Yang Q, et al. G3-C12 peptide reverses galectin-3 from foe to friend for active targeting cancer treatment. Mol Pharm. 2015;12:4124–4136.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.